Navigation Links
Hernia Publishes a Unique Three Year Pre-Clinical Study of absorbable TIGR® Matrix Surgical Mesh Versus a Permanent Mesh
Date:10/6/2011

SINGAPORE, Oct. 6, 2011 /PRNewswire/ -- Novus Scientific today announced the peer-reviewed publication of unique pre-clinical data on TIGR® Matrix Surgical Mesh – the world's first long-term absorbable surgical mesh.

The study, which was presented Online First in Hernia - The World Journal of Hernia and Abdominal Wall Surgery, describes the results of three years of functional implantation of TIGR® Matrix versus a permanent mesh in a sheep model.

This is the longest preclinical evidence ever published on surgical mesh, and it reveals key differences in outcome when comparing TIGR® Matrix to a permanent mesh. As TIGR® Matrix was absorbed over time, it was replaced by connective tissue that had higher collagen content than that surrounding the permanent control mesh. Over time, the foreign-body response to TIGR® Matrix declined significantly while it remained persistent in the control group.

"As TIGR® Matrix is the worlds first long-term absorbable mesh and also the first surgical mesh product with time-dependent mechanical characteristics, we wanted to substantiate how the unique design affects the tissue in terms of regenerated structure and stability." – said Henrik Hjort, first author and co-inventor of TIGR® Matrix. "We believe that the dual-fibre mechanics and resultant gradually increasing compliance can lead to long-lasting results which are indicated by the lack of defect recurrences in this study. A range of clinical studies are underway to examine the results of repair using TIGR® Matrix in a variety of soft tissue reinforcement applications to further demonstrate the benefits to the surgical community."

As stated in the publication: "As the resorbable test mesh gradually degraded it was replaced by a newly formed collagen matrix with an increasing ratio of collagen type I/III, indicating a continuous remodeling of the collagen towards a strong connective tissue." Furthermore: "The general connective tissue layer formed was thicker around the test mesh compared to the control." Hjort H, et al. (2011) Hernia. doi: 10.1007/s10029-011-0885-y.

The study was performed at Biomatech, an independent contract research company that is part of the NAMSA group.

Hernia – The World Journal of Hernia and Abdominal Wall Surgery is published by Springer (www.springerlink.com) and the article link can be found here: http://www.springerlink.com/content/c033k26015677312/

TIGR® Matrix  Surgical Mesh is available for sale in the U.S. and Europe.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. For comprehensive information visit our PRESSROOM: http://www.mynewsdesk.com/pressroom/novus-scientific

TIGR® is a trademark of Novus Scientific Pte. Ltd

CONTACT:  
Mark Hawthorne: +44 7748 988705 - mark.hawthorne@novusscientific.com


'/>"/>
SOURCE Novus Scientific
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
2. Reportlinker Adds Global Hernia Repair Devices Industry
3. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
4. Ethicon, Inc. Introduces Two Innovative Devices for Minimally Invasive Hernia Repair During American College of Surgeons (ACS) Annual Meeting
5. TIGR® Matrix Surgical Mesh - Exhibited Ahead of Anticipated CE Mark Approval at European Hernia Society 2011, Ghent, Belgium
6. MetroSouth Surgeon Pioneers Hybrid Treatment of Large Hiatal Hernias and Reflux
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
9. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
10. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
11. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):